Single-dose injectable nanovaccine-in-hydrogel for robust cancer immunotherapy
The present variants of cancer immunotherapy such as immune checkpoint blockades only benefit a small subset of patients due to its immunosuppressive tumor microenvironment. The capacity to vaccinate tumors and reduce immunosuppression ...